Avita Medical (RCEL) Q2 2026: Revenue Guidance Raised to $89M as Portfolio Adoption Accelerates

2026-08-06 | By EarningsIQ Research

Avita Medical’s portfolio strategy is gaining traction, driving a notable guidance raise and a near-term path to cash flow breakeven. Underlying adoption of Resell and new products is broadening across accounts, supported by a more stable reimbursement environment. Management’s focus on operating discipline and cash generation signals a business model entering a new phase of scalability and financial resilience.

Summary

• Portfolio Expansion Drives Confidence: Resell, Cohelix, and Permiaderm adoption is deepening across U.S. and international markets.
• Financial Discipline Unlocks Scalability: Operating expenses remain flat as revenue scales, supporting a credible cash flow inflection.
• Reimbursement Simplification Tailwind: Transition to national CPT codes in 2027 expected to streamline adoption and sales execution.

Business Overview

Avita Medical (RCEL) develops and commercializes regenerative skin and wound care technologies. The company’s core product, Resell, is a skin cell suspension system used for acute wounds and burns. Complementary products Cohelix, a synthetic wound matrix, and Permiaderm, a wound temporizer, enable a full-portfolio approach for hospital customers. Revenue is generated through direct sales to hospitals and clinics, with the U.S. market as the primary driver and early-stage international expansion underway.

Performance Analysis

Q2 marked a step-change in Avita’s commercial momentum, with revenue up 18% YoY and 13% sequentially, surpassing the $20 million quarterly mark for the first time. The U.S. remains the anchor market, with Resell contributing $18.5 million, while international revenue, though still modest, grew 26% sequentially as regulatory approvals unlock new regions. Cohelix and Permiaderm, though smaller, are showing early adoption signals and represent incremental growth levers.

Gross margin held firm above 81%, despite increased contribution from newer, lower-margin products. The company maintained flat operating expenses compared to Q1 and achieved a 6% YoY reduction, demonstrating that the commercial structure put in place in 2025 is scaling without incremental cost burden. Net cash use improved sharply to $3.2 million, and Avita ended the quarter with $11.1 million in cash and equivalents, reinforcing liquidity ahead of the projected Q4 cash flow breakeven.

• Mix Shift Impact: While Cohelix and Permiaderm dilute gross margin slightly, they add gross profit without driving up operating costs.
• Operating Leverage Materializes: Revenue growth outpaces expense growth, accelerating the path to profitability.
• Cash Conversion Cycle Improvement: Faster collections and normalized seasonal payments drove a significant reduction in cash burn.

Resell remains the primary engine, but the growing contribution from new products is broadening the revenue base and supporting a more durable growth trajectory.

Executive Commentary

Strategic Positioning

1. Portfolio Penetration and Clinical Integration

Avita’s three-product suite is gaining traction within hospital accounts, with 25 hospitals now trialing all products. Clinical feedback is positive, and the company is focused on maximizing cross-product synergies to drive deeper account penetration and recurring utilization.

2. Reimbursement Simplification as Growth Catalyst

The transition to national CPT codes for Resell procedures in 2027 will eliminate regional reimbursement complexity, reducing administrative barriers for physicians and sales teams. Management expects this shift to accelerate adoption and allow commercial resources to focus on clinical and economic value rather than coding challenges.

3. Operating Model Scalability

Flat operating expenses amid double-digit revenue growth highlight a scalable cost structure, reflecting the benefits of prior commercial restructuring. This discipline supports the company’s updated guidance for cash flow breakeven in Q4 2026 and positions Avita for self-funded growth.

4. Clinical Evidence and Market Access

Ongoing clinical studies, such as COHELIX-1 and Permiaderm-1, are building the evidence base needed for broader hospital adoption and improved value analysis committee (VAC) approvals. Interim data for Cohelix shows faster skin graft readiness versus leading competitors, with full datasets and publications expected later this year.

Key Considerations

This quarter marks a strategic inflection for Avita, as commercial momentum, reimbursement clarity, and cost discipline converge to support sustainable growth. Investors should weigh the following:

• Reimbursement Clarity Drives Adoption: National CPT codes will streamline physician workflow, likely unlocking underpenetrated accounts.
• Product Mix Evolution: As Cohelix and Permiaderm mature, monitoring their margin impact and contribution to recurring revenue will be critical.
• Cash Flow Inflection: Achieving breakeven in Q4 2026 reduces capital risk and enhances Avita’s strategic flexibility.
• Clinical Data as Adoption Lever: Publication of pivotal studies may accelerate VAC approvals and competitive differentiation.

Risks

Execution risk remains around the transition to new reimbursement codes, as any delays or confusion could disrupt momentum. Early-stage adoption of Cohelix and Permiaderm is not yet proven at scale, and margin dilution from mix shift could intensify if uptake outpaces price optimization. International expansion is nascent and may face regulatory or commercial hurdles. Analyst questions surfaced concerns about transitional “air pockets” during coding changes, but management is proactively educating customers to mitigate this risk.

Forward Outlook

For Q3 2026, Avita expects continued sequential revenue growth and further reduction in cash burn.

• Q4 2026 projected to reach cash flow breakeven and begin generating positive cash.
• Full-year 2026 revenue guidance raised to $86 million to $89 million (20% to 24% YoY growth).

Management cited predictable customer forecasting, stable reimbursement, and broadening portfolio adoption as key drivers of the guidance raise. Additional factors include:

• Continued ramp of Resell Go Mini in smaller wounds
• Steady progress in Cohelix VAC reviews and early Permiaderm traction

Takeaways

Avita’s Q2 results and guidance raise signal a business model reaching critical mass. The company’s focus on execution, portfolio integration, and reimbursement clarity is translating into tangible financial milestones.

• Portfolio Adoption Accelerates: Resell remains the anchor, but Cohelix and Permiaderm are gaining ground, broadening the revenue base.
• Operating Leverage Realized: Flat expenses and improving cash conversion support a credible path to breakeven and self-funding.
• Reimbursement Shift as Structural Tailwind: The move to national CPT codes in 2027 should reduce friction and unlock latent demand, but the transition will require careful execution and education.

Conclusion

Avita Medical enters the second half of 2026 with accelerating commercial momentum, a clear line of sight to cash generation, and a multi-pronged product strategy. The convergence of reimbursement simplification, operating discipline, and clinical evidence positions the company for a structurally stronger growth trajectory.

Industry Read-Through

Avita’s experience highlights the compounding value of reimbursement clarity and portfolio breadth in medtech commercial models. Other wound care and regenerative medicine firms should note the impact of national coding transitions on adoption velocity and sales resource efficiency. The company’s disciplined approach to operating leverage and cash conversion offers a template for scaling specialty device businesses without overextending cost bases. Additionally, the early traction of new products underscores the importance of robust clinical evidence and proactive VAC engagement for market access in hospital-driven markets.

RCEL Healthcare Medical Devices Wound Care Reimbursement Portfolio Expansion Operating Leverage Cash Flow